with the other 7 BoNT serotypes, BoNT/H has an N-terminal two-thirds that is most homologous to BoNT/F and a C-terminal one-third that is most homologous to BoNT/A [16] . In its initial description, BoNT/H was not neutralized by existing polyclonal antitoxins, which included a US Army-supplied equine polyclonal heptavalent (targeting serotypes A-G) F(ab′) 2 botulinum antitoxin at anti-A and anti-F antitoxin to toxin potency ratios as high as 595:1 [15] . Neutralization only occurred at an anti-A antitoxin ratio of 1190:1 [15] . In more recent work, BoNT/H was neutralized by research antitoxins at ratios ranging from 20:1 to 200:1; for neutralization, using the therapeutic licensed BAT, a ratio of >500:1 was required [18] . We therefore evaluated our existing mAbs to BoNT/A and BoNT/F for BoNT/H binding, evolved one of these mAbs for higher-affinity BoNT/H binding, and thereby created a 3-mAb combination that potently neutralizes BoNT/H.
METHODS

Bacterial Strain and Production of BoNT/H
C. botulinum type Bh strain IBCA10-7060 culture filtrate was prepared, sterilized, and titrated by the mouse bioassay as previously described [15] . Culture filtrates were concentrated approximately 5-fold, using Amicon concentrators (Millipore, Bedford, Massachusetts), and the resultant concentrations (50% mouse lethal doses [MLD 50 ] per milliliter) of BoNT/B2 and BoNT/H were determined (Supplementary Materials).
Mouse Bioassay Neutralization Studies With Equine Polyclonal Antitoxins
Mouse bioassay neutralization studies were performed using sterile culture filtrate and monovalent polyclonal equine antitoxins A, B, and F (Centers for Disease Control and Prevention, Atlanta, Georgia) under institutional animal care and use committee-approved protocols, as previously described [15] .
Mouse Bioassay Neutralization Studies With Monoclonal Antibodies
Mixtures of either 2 or 3 monoclonal antibodies in equimolar amounts were prepared to a final protein concentration of 1 mg/ mL in phosphate-buffered saline (PBS). mAb mixtures were serially diluted with gel phosphate diluent, and 0.1 ml of these mixtures were combined with 0.5 mL of culture filtrate, incubated at room temperature for 30 minutes, and then injected intraperitoneally, as is done in the standard mouse bioassay with equine monovalent polyclonal antitoxins (Supplementary Materials). In these studies, BoNT/B activity in culture filtrate was neutralized by using either polyclonal anti-B antitoxin or a combination of 3 mAbs known to bind to and potently neutralize BoNT/B2 [28] .
mAb Generation, Production, Purification, and Characterization All immunoglobulin G (IgG) antibodies were produced recombinantly from stable Chinese hamster ovary (CHO) cell lines by cloning the V H and V k genes of scFv as previously described [26, 29] . All mAbs were expressed with human γ1/k constant domains and purified on protein G (Pharmacia). IgG purity was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the concentration was determined by measuring the absorbance at 280 nm.
Screening of mAbs for Binding to BoNT/H by Enzyme-Linked Immunosorbent Assay (ELISA) Meso Scale Diagnostic (MSD) 96-well plates were coated with a BoNT-specific IgG (as described below) at a final concentration of 4 µg/mL, 30 µL/well, and incubated overnight at 4°C. After blocking with 2% milk powder in PBS for 30 minutes, 1:1 PBS-diluted culture filtrate samples (pH 7.4) were added to each well. Binding was detected by adding an equimolar mixture of SULFO-TAGlabeled mAbs CR2 and RAZ1. Plates were read in a MSD SECTOR Imager 2400 instrument. The concentrations of BoNT/H and BoNT/B2 in culture filtrate were determined from standard curves as previously described [30] . For measurement of the BoNT/B2 concentration, 2B18.3 IgG was used for capture, and SULFO-TAG-labeled 1B10.1 IgG was used for detection. For quantification of the BoNT/H concentration, 6F5.1 IgG was used for capture, and SULFO-TAG-labeled RAZ1 was used for detection. Pure BoNT/A1 (for BoNT/H measurements) and BoNT/B1 (Metabiologics; for BoNT/B2 measurements) were used to construct standard curves. Culture filtrate or BoNT/B1 standard was measured in triplicate, using 3 wells on the same plate. Plates were coated with either 6F5.1 or 2B18.3 IgG at a final concentration of 4 µg/mL, 30 µL/well, and incubated overnight at 4°C. Serially diluted culture filtrate samples or BoNT standards were added to each well, incubated for 1 hour, and washed, and SULFO-TAG detection mAb was added. Plates were read in a SECTOR Imager 2400 instrument.
Measurement of BoNT/H and BoNT/B2 Concentrations by Flow Fluorimetry
The concentrations of BoNT/H and BoNT/B2 in culture filtrate were measured with a KinExA 3200 instrument (Sapidyne) as previously described [29, 31] , using mAbs RAZ1 and 1B10.1, respectively. Culture filtrate containing BoNT/H and BoNT/B2 was studied at a concentration estimated to be >10-fold above the value of the equilibrium dissociation binding constant [K D ] of the mAb for its target toxin to generate a concentration-controlled curve for greater accuracy in measuring BoNT concentrations. mAb-containing solutions were serially diluted 2-fold 13 times in a constant concentration of culture filtrate, from >10-fold above to <0.01-fold below the estimated BoNT/H or BoNT/B2 concentrations, to capture a complete binding curve. After equilibrium was achieved, samples were passed over a flow cell packed with Sepharose 4 Fast Flow beads (GE Healthcare) covalently coupled with the measuring mAb. An Alexa-647-labeled mAb binding a nonoverlapping BoNT epitope (4E17.2A for BoNT/H, B6.1 for BoNT B2) was then passed over the flow cell, producing a signal proportional to the free BoNT in each sample. An analysis curve yielding values for K D and the binding concentrations of the BoNTs was generated using KinExA Pro software (version 4.0.12) and a 1:1 reverse-binding model.
Measurement of Antibody-Binding Affinity and Kinetics by Flow Fluorimetry
The affinity (measured by the K D ) for BoNT/A1, BoNT/B2 (kind gift of Eric Johnson), BoNT/F1, BoNT/F5 (kind gift of Susan Maslanka), and BoNT/H was measured in a KinExA 3200 instrument as described above and previously [29, 32] , using 1:2 serial dilutions of 13 samples of mAb in a constant concentration of pure BoNT/A1 (Metabiologics), pure BoNT/ B2, or culture filtrate containing BoNT/H at a concentration of ≤10-fold above the estimated K D of the interaction, to ensure a K D -controlled analysis curve. The association rate constant (k on ) was measured using either pure BoNT or culture filtrate by passing 0.5-mL volumes over a fresh BoNT-binding bead pack as the mixture came to equilibrium, at intervals of approximately 700 seconds. Free BoNT was detected at each interval with Alexa-647-labeled antibody as described above. The time-dependent exponential decrease in concentration of free BoNT as a function of time was fitted to a standard bimolecular rate equation, using KinExA Pro software to determine k on . k off was calculated from the product of k on × K D .
Measurement of Yeast-Displayed scFv Affinity for BoNT/H
K D was also determined using yeast-displayed scFv and flow cytometry as described previously [29, 33] . Yeasts were incubated with 5 different concentrations of crude BoNT/H in diluted culture filtrate that ranged from 10 times above to 10 times below the K D at 4°C for 30 minutes in florescence-activated cell-sorting buffer with proteinase inhibitor and 20 mM ethylenediaminetetraacetic acid (EDTA). Binding of BoNT/H to yeast-displayed scFv was detected after incubation with 2 µg/mL of RAZ1 IgG, followed by incubation with 1 µg/mL of goat anti-human phycoerythrin and anti-SV5-647. Each K D was determined in triplicate.
RESULTS
Structural Analysis of BoNT/H
BoNT/H has an N-terminal third that is most homologous to the hybrid subtype BoNT/F5, a unique middle third that is most homologous to BoNT/F1, and a C-terminal third that is most homologous to BoNT/A [16] . BoNT/H and BoNT/A1 are only 49.8% identical at the amino acid level but share 92.2% identity in their H CC and 73.1% identity in their H CN domains [16] (Figure 1 ). BoNT/H is only 52.8% identical to BoNT/F1, with hybrid subtype BoNT/F5 [35] having higher identity (61.8%), especially in its LC (80.1%) [16] . To visualize how these differences influence BoNT/A and BoNT/F antibody binding, BoNT/H amino acid differences were modeled on the structures of BoNT/A1 and BoNT/F1 (Figure 1 ). BoNT/H and BoNT/A1 share significant surface identity in their H CC domains and to a lesser extent their H CN domains (Figure 1 ), suggesting that BoNT/A1 antibodies that bind these domains could bind BoNT/H. For the remainder of BoNT/H (its LC and H N ), the surface identities with BoNT/A1 and BoNT/F1 are comparable to the low identities observed between the BoNT/A1 and BoNT/F1 serotypes ( Figure 1 ). These low identities made it unlikely that mAbs binding the H N or LC of BoNT/ A1 or BoNT/F1 would bind BoNT/H.
Identification of mAbs Likely to Bind BoNT/H
On the basis of structural analyses, >100 published [26, 29, 32, 36, 37] and unpublished human or murine mAbs were surveyed to identify mAbs that might bind BoNT/H, based on the criteria that they bound either the BoNT/A1 H C or the BoNT/F1 H N or LC (Table 1 and . Three mAbs (3D12, CR1, and 4E17.2) had been mapped to the specific amino acids that were energetically important for binding [37, 38] . These amino acids in BoNT/H were identical for 3D12 and were highly conserved for CR1 and 4E17.2, suggesting a high probability of their binding to BoNT/H.
Determination of Amounts of BoNT/B2 and BoNT/H in IBCA10-7060 Culture Filtrates
A sandwich ELISA was developed as previously described (Supplementary Figure 1 ) [30] to measure the concentrations of each BoNT present in culture filtrate. By ELISA, the culture filtrate concentration of BoNT/B2 was 35.3 nM (5.3 µg/mL) and that of BoNT/H was 11.3 nM (1.7 µg/mL). The concentrations of BoNT/B2 (33 nM; 4.96 µg/mL) and BoNT/H (7.53 nM; 1.13 µg/mL) were also measured using flow fluorimetry in a KinExA 3200 instrument (Figure 3) . Values for the 2 methods were within 7% of each other for BoNT/B2 and within 34% for BoNT/H. The greater discrepancy for BoNT/H likely resulted from less accurate ELISA measurements due to lack of pure BoNT/H for standard curve construction and the binding of BoNT/B2 to the crossreactive 4E17.2 mAb. We repeated measurement of BoNT/B2 and BoNT/H concentrations, using the KinExA 3200 instrument, on 4 independent culture filtrates of strain IBCA10-7060. Mean BoNT/B2 concentrations (±SD) were 6.89 ± 3.58 µg/mL, and mean BoNT/H concentrations (±SD) were 1.31 ± 0.93 µg/mL. On one culture filtrate sample, mouse lethality was determined before and after the addition of anti-B antitoxin, enabling measurement of lethality due to BoNT/B2 and to BoNT/H (Supplementary Table 1 ). The relative lethality of BoNT/B2 to that of BoNT/H in this culture filtrate was 24-fold as previously reported [15] , with 4.4-fold due to the higher concentration of BoNT/B2 and 5.47-fold due to the higher specific activity of BoNT/B2.
Evaluation of Existing mAbs for Binding to BoNT/H
Fourteen BoNT/A and BoNT/F mAbs (Table 1) were screened for binding to BoNT/H by ELISA, including 2 control BoNT/F H C mAbs (6F3 and 6F4) not expected to bind to BoNT/H. For the BoNT/A mAbs, 3D12 and its derivative, RAZ1, gave the strongest signals, with binding also observed for CR1, CR2 (the CR1 derivative), S25, and 4E17.2 ( Figure 4 ). For the BoNT/F mAbs, 6F12 gave the strongest signal, with no binding observed for BoNT/F H C mAbs 6F3 and 6F4. mAb affinity for BoNT/H was measured by flow fluorimetry in a KinExA 3200 instrument [29, 32, 37] . RAZ1 bound to BoNT/H with very high affinity (K D = 4.96 × 10 −12 M, similar to its affinity for BoNT/A1; Table 2 ). CR2 bound to BoNT/H with high affinity (K D = 5.37 × 10 −9 M), approximately 400-fold Figure 1 . Amino acid and structural identity of botulinum neurotoxin type H (BoNT/H) holotoxin and domains compared to BoNT/A and BoNT/F. The table indicates the amino acid percentage identity between the sequence of BoNT/H holotoxin and its domains [34] and the other BoNTs indicated. The figure shows the surface amino acid differences between BoNT/H and BoNT/A1 (A), BoNT/F1 (B ), and BoNT/F5 (C) and the difference between BoNT/F1 and BoNT/A1 (D ). Identical amino acids are colored white, and nonidentical amino acids are in increasing shades of red as a function of the relatedness in amino acid side chain. The models were constructed using pyMol on the Xray crystal structure of BoNT/A1 (3BTA; A and D ) or on a model of BoNT/F built from the X-ray crystal structure of the BoNT/F1 light chain (LC; 2A97) and the BoNT/A1 heavy chain (HC; 3BTA; B and C ).
lower than its affinity for BoNT/A1. This finding is consistent with observed amino acid differences in the CR2 epitope on the BoNT/H H CC . Some of these amino acid differences are identical to those in BoNT/A2 [37] , and the CR2 K D for BoNT/H is only 10-fold lower than its K D for BoNT/A2 [37] . mAb S25
bound BoNT/H with moderate affinity (K D = 1.44 × 10 −8 M).
We also measured the affinity for BoNT/H of BoNT/A mAbs Aa (K D = 3 × 10 −12 M) and Ab (K D = 2.14 × 10 −9 M), 2 of the 3 mAbs in XOMA 3AB [27] . Figure 2 ) [29] . It was postulated that selection for higher-affinity BoNT/F1 binding would result in increased affinity for BoNT/ H, so additional selections were done using pure BoNT/F1 to also avoid improving the affinity of cross-reactive 4E17.2A for BoNT/B2, rather than BoNT/H. For selections done on BoNT/F1, a higher-affinity mAb (4E17.2B) was identified that had 3 mutations in CDRH1 and a 30-fold and 8.4-fold increase in affinity for BoNT/F1 and BoNT/H, respectively ( Table 2 and The terms "LC" ("light chain"; molecular weight, 50 000 Da) and "HC" ("heavy chain"; molecular weight, 100 000 Da) are historical and refer to the relative molecular weights of the 2 polypeptide chains of BoNT after reduction of the disulfide bond.
Supplementary Figure 2 ). For selections done on BoNT/H, mutations were identified in CDRH3, L1, and L2 that each increased the affinity of yeast-displayed scFv 3-4-fold for BoNT/H. Mutations in these CDRs were combined into a single mAb (4E17.2C), which had a 59-fold higher affinity for BoNT/ H. The affinity of 4E17.2C was further increased 8.6-fold by randomly introducing mutations into the 4E17.2C scFv gene and selecting for higher-affinity BoNT/H binding, yielding mAb 4E17.2D (K D = 1.48 × 10 −10 M) with a >500-fold affinity for BoNT/H. During the affinity maturation process, the affinity of 4E17-based mAbs for BoNT/B2 decreased 14-fold to 5.12 × 10 −7 M ( Table 2 ).
Neutralization of BoNT/H in Mice by mAb Combinations
All mice receiving as little as 8.25 µg of the mAb pair RAZ1 and CR2 survived challenge with 28 MLD 50 of BoNT/H but had mild botulism symptoms (Table 3) . Addition of a low-affinity third mAb (4E17.2B) showed equivalent protection. Replacement of 4E17.2B with the higher-affinity 4E17.2C resulted in 5 of 8 mice surviving a 72.5 LD 50 challenge. Combining RAZ1 and CR2 with the highest-affinity 4E17.2D protected all mice challenged with 280 LD 50 of BoNT/H at a mAb dose as low as 5 µg total antibody (Table 3) . No mice survived at a 2.5 µg mAb dose, resulting in an ED 50 (the dose at which 50% of mice survive) estimated to be 3.75 µg. A combination (Table 3) .
DISCUSSION
The results demonstrate the value of having developed wellcharacterized mAb binding epitopes that are conserved between 
